MedTrace Logo

Safety Study of Four Doses of the Study Drug, HF1020 in Healthy Volunteers

NCT01425450 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-10-31

No results posted yet for this study

Summary

The study aims to:

* study the safety of the drug (HF1020) in healthy male adults
* study how well the study drug (HF1020) is tolerated in healthy male adults
* find the maximum dose that is tolerated in healthy male adults

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

HF1020

Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.

DRUG

HF1020 placebo

Single dose: HF1020 placebo capsule

Sponsors & Collaborators

  • Trident Pharmaceuticals Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01425450 on ClinicalTrials.gov